Chitosan self-assembled polymeric nanoparticles for percutaneous delivery of betamethasone in contact dermatitis
OBJECTIVE: The study was performed with an aim to investigate the efficiency of two treatment options in experimental nickel-induced contact dermatitis (CT), with either betamethasone or chitosan cross-linked nano-encapsulated betamethasone lanoline solutions (nano-betamethasone).
METHODS: Male Wistar rats were used. The differences were compared based on lesion visual appearance, skinfold thickness, white blood cell count (WBC), erythrocyte sedimentation rate (ESR), blood serum prooxidant-antioxidant balance (thiobarbituric acid reactive substances, TBARS; supersoxide dismutase, SOD; catalase, KAT), blood cytokine profile (TNF-α, IL-1β, IL-10, and IL-4), and histological examination of affected skin.
RESULTS: All animals treated with nickel sulfate developed CT and systemic inflammatory response on day 12, which only slightly lessened, if left untreated, on day 20. The therapeutic effectiveness of nano-betamethasone was significantly far superior (p < 0.01) compared to betamethasone. Specifically, the visual appearance of lesion severity of betamethasone vs. nano-betamethasone ± SD was 1.82 ± 0.18 vs. 1.17 ± 0.24 points, skinfold thickness-2.68 ± 0.12 vs. 2.12 ± 0.10 mm, ESR-6.38 ± 0.27 vs. 5.12 ± 0.20 mm/h, WBC-8.47 ± 0.28 vs. 7.17 ± 0.24 109/L, TBARS-1.09 ± 0.04 vs. 0.94 ± 0.02 µmol/L, SOD-3.38 ± 0.26 vs. 4.12 ± 0.18 r.u./L, KAT-11.54 ± 0.14 vs. 10.02 ± 0.19 mkatal/L, respectively. The nano-betamethasone formulation was also more effective (p < 0.01) in increasing anti-inflammatory cytokines level, IL-10 (8.96 ± 0.32 vs. 7.54 ± 0.52 pg/mL) and IL-4 (13.16 ± 0.45 vs. 11.43 ± 0.58 pg/mL); and decreasing in pro-inflammatory TNF-α (20.94 ± 2.30 vs. 26.98 ± 1.16 pg/mL) and IL-1β (19.35 ± 1.28 vs. 24.77 ± 1.75 pg/mL), respectively. These findings were also supported with histological examination.
CONCLUSIONS: Nano-betamethasone may be considered as a more successful transcutaneous therapy for managing contact dermatitis compared to ointments consisting of betamethasone in traditional form.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
---|---|
Enthalten in: |
Drug development and industrial pharmacy - 47(2021), 8 vom: 04. Aug., Seite 1310-1317 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hudan-Tsilo, Ivanna [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 26.04.2022 Date Revised 27.04.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/03639045.2021.1989457 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM331533286 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM331533286 | ||
003 | DE-627 | ||
005 | 20231225213658.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/03639045.2021.1989457 |2 doi | |
028 | 5 | 2 | |a pubmed24n1105.xml |
035 | |a (DE-627)NLM331533286 | ||
035 | |a (NLM)34612134 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hudan-Tsilo, Ivanna |e verfasserin |4 aut | |
245 | 1 | 0 | |a Chitosan self-assembled polymeric nanoparticles for percutaneous delivery of betamethasone in contact dermatitis |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.04.2022 | ||
500 | |a Date Revised 27.04.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a OBJECTIVE: The study was performed with an aim to investigate the efficiency of two treatment options in experimental nickel-induced contact dermatitis (CT), with either betamethasone or chitosan cross-linked nano-encapsulated betamethasone lanoline solutions (nano-betamethasone) | ||
520 | |a METHODS: Male Wistar rats were used. The differences were compared based on lesion visual appearance, skinfold thickness, white blood cell count (WBC), erythrocyte sedimentation rate (ESR), blood serum prooxidant-antioxidant balance (thiobarbituric acid reactive substances, TBARS; supersoxide dismutase, SOD; catalase, KAT), blood cytokine profile (TNF-α, IL-1β, IL-10, and IL-4), and histological examination of affected skin | ||
520 | |a RESULTS: All animals treated with nickel sulfate developed CT and systemic inflammatory response on day 12, which only slightly lessened, if left untreated, on day 20. The therapeutic effectiveness of nano-betamethasone was significantly far superior (p < 0.01) compared to betamethasone. Specifically, the visual appearance of lesion severity of betamethasone vs. nano-betamethasone ± SD was 1.82 ± 0.18 vs. 1.17 ± 0.24 points, skinfold thickness-2.68 ± 0.12 vs. 2.12 ± 0.10 mm, ESR-6.38 ± 0.27 vs. 5.12 ± 0.20 mm/h, WBC-8.47 ± 0.28 vs. 7.17 ± 0.24 109/L, TBARS-1.09 ± 0.04 vs. 0.94 ± 0.02 µmol/L, SOD-3.38 ± 0.26 vs. 4.12 ± 0.18 r.u./L, KAT-11.54 ± 0.14 vs. 10.02 ± 0.19 mkatal/L, respectively. The nano-betamethasone formulation was also more effective (p < 0.01) in increasing anti-inflammatory cytokines level, IL-10 (8.96 ± 0.32 vs. 7.54 ± 0.52 pg/mL) and IL-4 (13.16 ± 0.45 vs. 11.43 ± 0.58 pg/mL); and decreasing in pro-inflammatory TNF-α (20.94 ± 2.30 vs. 26.98 ± 1.16 pg/mL) and IL-1β (19.35 ± 1.28 vs. 24.77 ± 1.75 pg/mL), respectively. These findings were also supported with histological examination | ||
520 | |a CONCLUSIONS: Nano-betamethasone may be considered as a more successful transcutaneous therapy for managing contact dermatitis compared to ointments consisting of betamethasone in traditional form | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Chitosan nanoparticles | |
650 | 4 | |a betamethasone | |
650 | 4 | |a contact dermatitis | |
650 | 4 | |a cytokines | |
650 | 4 | |a prooxidant-antioxidant balance | |
650 | 4 | |a skin histology | |
650 | 7 | |a Thiobarbituric Acid Reactive Substances |2 NLM | |
650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
650 | 7 | |a Interleukin-10 |2 NLM | |
650 | 7 | |a 130068-27-8 |2 NLM | |
650 | 7 | |a Interleukin-4 |2 NLM | |
650 | 7 | |a 207137-56-2 |2 NLM | |
650 | 7 | |a Chitosan |2 NLM | |
650 | 7 | |a 9012-76-4 |2 NLM | |
650 | 7 | |a Betamethasone |2 NLM | |
650 | 7 | |a 9842X06Q6M |2 NLM | |
650 | 7 | |a Superoxide Dismutase |2 NLM | |
650 | 7 | |a EC 1.15.1.1 |2 NLM | |
700 | 1 | |a Tokarskyy, Oleksandr |e verfasserin |4 aut | |
700 | 1 | |a Shevchuk, Oksana |e verfasserin |4 aut | |
700 | 1 | |a Korda, Mykhaylo |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Drug development and industrial pharmacy |d 1994 |g 47(2021), 8 vom: 04. Aug., Seite 1310-1317 |w (DE-627)NLM077783093 |x 1520-5762 |7 nnns |
773 | 1 | 8 | |g volume:47 |g year:2021 |g number:8 |g day:04 |g month:08 |g pages:1310-1317 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/03639045.2021.1989457 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 47 |j 2021 |e 8 |b 04 |c 08 |h 1310-1317 |